ID

39717

Beschreibung

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063); ODM derived from: https://clinicaltrials.gov/show/NCT01390844

Link

https://clinicaltrials.gov/show/NCT01390844

Stichworte

Versionen (1)
  1. 12.02.20 12.02.20 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

12. Februar 2020

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Hepatitis C, Chronic NCT01390844

Englisch

Eligibility Hepatitis C, Chronic NCT01390844

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
previously documented chc genotype 1 infection. other or mixed genotypes are not eligible.
Beschreibung

Chronic Hepatitis C Genotype

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0524910
UMLS CUI [1,2]
C1533728
liver biopsy with histology consistent with chc and no other etiology.
Beschreibung

Biopsy of liver | Histology Consistent with Chronic Hepatitis C

Datentyp

boolean

Alias
UMLS CUI [1]
C0193388
UMLS CUI [2,1]
C0344441
UMLS CUI [2,2]
C0332290
UMLS CUI [2,3]
C0524910
participants with cirrhosis must have an ultrasound/imaging study within 6 months of screening (or between screening and day 1) with no findings suspicious for hepatocellular carcinoma
Beschreibung

Liver Cirrhosis Ultrasonography | Liver Cirrhosis Imaging study | Absence Liver findings Suspicious Liver carcinoma

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0023890
UMLS CUI [1,2]
C0041618
UMLS CUI [2,1]
C0023890
UMLS CUI [2,2]
C1881134
UMLS CUI [3,1]
C0332197
UMLS CUI [3,2]
C0426686
UMLS CUI [3,3]
C0750493
UMLS CUI [3,4]
C2239176
failed previous treatment (of at least 12 weeks) with pegylated interferon (alfa-2a or alfa-2b) plus rbv
Beschreibung

Prior Therapy failed | Peginterferon alfa-2a plus Ribavirin | Peginterferon alfa-2b plus Ribavirin

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0231175
UMLS CUI [2,1]
C0391001
UMLS CUI [2,2]
C0332287
UMLS CUI [2,3]
C0035525
UMLS CUI [3,1]
C0796545
UMLS CUI [3,2]
C0332287
UMLS CUI [3,3]
C0035525
weight between 40 kg and 125 kg, inclusive
Beschreibung

Body Weight

Datentyp

boolean

Alias
UMLS CUI [1]
C0005910
of 'local' ancestral descent
Beschreibung

Ancestors Local

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0870134
UMLS CUI [1,2]
C0205276
sexually active males and females of child-bearing potential must agree to use a medically accepted method of contraception
Beschreibung

Gender Sexually active Contraceptive methods | Childbearing Potential Contraceptive methods

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0241028
UMLS CUI [1,3]
C0700589
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0700589
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
co-infected with the human immunodeficiency virus (hiv) or hepatitis b virus
Beschreibung

Human immunodeficiency virus (HIV) coinfection | HBV coinfection

Datentyp

boolean

Alias
UMLS CUI [1]
C4062778
UMLS CUI [2]
C2242656
required discontinuation of previous interferon or rbv regimen for an adverse event considered to be possibly or probably related to rbv and/or interferon
Beschreibung

Interferon To be stopped | Ribavirin To be stopped | Adverse event Relationship Ribavirin | Adverse event Relationship Interferon

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3652465
UMLS CUI [1,2]
C1272691
UMLS CUI [2,1]
C0035525
UMLS CUI [2,2]
C1272691
UMLS CUI [3,1]
C0877248
UMLS CUI [3,2]
C0439849
UMLS CUI [3,3]
C0035525
UMLS CUI [4,1]
C0877248
UMLS CUI [4,2]
C0439849
UMLS CUI [4,3]
C3652465
treatment with rbv within 90 days and any interferon-alpha within 1 month prior to screening
Beschreibung

Ribavirin Recent | Interferon-alpha Recent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0035525
UMLS CUI [1,2]
C0332185
UMLS CUI [2,1]
C0002199
UMLS CUI [2,2]
C0332185
treatment for hepatitis c with any investigational medication or prior treatment with herbal remedies with known hepatotoxicity
Beschreibung

Therapeutic procedure Hepatitis C | Investigational New Drugs | Herbal medicine Associated with Hepatotoxicity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0019196
UMLS CUI [2]
C0013230
UMLS CUI [3,1]
C2240391
UMLS CUI [3,2]
C0332281
UMLS CUI [3,3]
C0235378
treatment with any investigational drug or participation in any interventional clinical trial within 30 days of the screening visit
Beschreibung

Investigational New Drugs | Study Subject Participation Status | Interventional Study

Datentyp

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C2348568
UMLS CUI [3]
C3274035
evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy
Beschreibung

Decompensated liver disease | Ascites | Bleeding varices | Hepatic Encephalopathy

Datentyp

boolean

Alias
UMLS CUI [1]
C4075847
UMLS CUI [2]
C0003962
UMLS CUI [3]
C0333106
UMLS CUI [4]
C0019151
diabetes and/or hypertension with clinically significant ocular examination findings
Beschreibung

Diabetes | Hypertensive disease | On examination - eye findings Clinical Significance

Datentyp

boolean

Alias
UMLS CUI [1]
C0011847
UMLS CUI [2]
C0020538
UMLS CUI [3,1]
C0437530
UMLS CUI [3,2]
C2826293
any condition the could interfere with participation in and completion of the trial
Beschreibung

Condition Interferes with Study Subject Participation Status | Condition Interferes with Completion of clinical trial

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C2348568
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C2732579
evidence of active or suspected malignancy, or history of malignancy within the last 5 years (except adequately treatment carcinoma in situ and basal cell carcinoma of the skin)
Beschreibung

Malignant Neoplasms | Malignant Neoplasm Suspected | Exception Carcinoma in Situ Treated | Exception Basal cell carcinoma Treated

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C0006826
UMLS CUI [2,2]
C0750491
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007099
UMLS CUI [3,3]
C1522326
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0007117
UMLS CUI [4,3]
C1522326
pregnant or breast-feeding
Beschreibung

Pregnancy | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Hepatitis C, Chronic NCT01390844

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Chronic Hepatitis C Genotype
Item
previously documented chc genotype 1 infection. other or mixed genotypes are not eligible.
boolean
C0524910 (UMLS CUI [1,1])
C1533728 (UMLS CUI [1,2])
Biopsy of liver | Histology Consistent with Chronic Hepatitis C
Item
liver biopsy with histology consistent with chc and no other etiology.
boolean
C0193388 (UMLS CUI [1])
C0344441 (UMLS CUI [2,1])
C0332290 (UMLS CUI [2,2])
C0524910 (UMLS CUI [2,3])
Liver Cirrhosis Ultrasonography | Liver Cirrhosis Imaging study | Absence Liver findings Suspicious Liver carcinoma
Item
participants with cirrhosis must have an ultrasound/imaging study within 6 months of screening (or between screening and day 1) with no findings suspicious for hepatocellular carcinoma
boolean
C0023890 (UMLS CUI [1,1])
C0041618 (UMLS CUI [1,2])
C0023890 (UMLS CUI [2,1])
C1881134 (UMLS CUI [2,2])
C0332197 (UMLS CUI [3,1])
C0426686 (UMLS CUI [3,2])
C0750493 (UMLS CUI [3,3])
C2239176 (UMLS CUI [3,4])
Prior Therapy failed | Peginterferon alfa-2a plus Ribavirin | Peginterferon alfa-2b plus Ribavirin
Item
failed previous treatment (of at least 12 weeks) with pegylated interferon (alfa-2a or alfa-2b) plus rbv
boolean
C1514463 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
C0391001 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C0035525 (UMLS CUI [2,3])
C0796545 (UMLS CUI [3,1])
C0332287 (UMLS CUI [3,2])
C0035525 (UMLS CUI [3,3])
Body Weight
Item
weight between 40 kg and 125 kg, inclusive
boolean
C0005910 (UMLS CUI [1])
Ancestors Local
Item
of 'local' ancestral descent
boolean
C0870134 (UMLS CUI [1,1])
C0205276 (UMLS CUI [1,2])
Gender Sexually active Contraceptive methods | Childbearing Potential Contraceptive methods
Item
sexually active males and females of child-bearing potential must agree to use a medically accepted method of contraception
boolean
C0079399 (UMLS CUI [1,1])
C0241028 (UMLS CUI [1,2])
C0700589 (UMLS CUI [1,3])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Human immunodeficiency virus (HIV) coinfection | HBV coinfection
Item
co-infected with the human immunodeficiency virus (hiv) or hepatitis b virus
boolean
C4062778 (UMLS CUI [1])
C2242656 (UMLS CUI [2])
Interferon To be stopped | Ribavirin To be stopped | Adverse event Relationship Ribavirin | Adverse event Relationship Interferon
Item
required discontinuation of previous interferon or rbv regimen for an adverse event considered to be possibly or probably related to rbv and/or interferon
boolean
C3652465 (UMLS CUI [1,1])
C1272691 (UMLS CUI [1,2])
C0035525 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
C0877248 (UMLS CUI [3,1])
C0439849 (UMLS CUI [3,2])
C0035525 (UMLS CUI [3,3])
C0877248 (UMLS CUI [4,1])
C0439849 (UMLS CUI [4,2])
C3652465 (UMLS CUI [4,3])
Ribavirin Recent | Interferon-alpha Recent
Item
treatment with rbv within 90 days and any interferon-alpha within 1 month prior to screening
boolean
C0035525 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0002199 (UMLS CUI [2,1])
C0332185 (UMLS CUI [2,2])
Therapeutic procedure Hepatitis C | Investigational New Drugs | Herbal medicine Associated with Hepatotoxicity
Item
treatment for hepatitis c with any investigational medication or prior treatment with herbal remedies with known hepatotoxicity
boolean
C0087111 (UMLS CUI [1,1])
C0019196 (UMLS CUI [1,2])
C0013230 (UMLS CUI [2])
C2240391 (UMLS CUI [3,1])
C0332281 (UMLS CUI [3,2])
C0235378 (UMLS CUI [3,3])
Investigational New Drugs | Study Subject Participation Status | Interventional Study
Item
treatment with any investigational drug or participation in any interventional clinical trial within 30 days of the screening visit
boolean
C0013230 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
C3274035 (UMLS CUI [3])
Decompensated liver disease | Ascites | Bleeding varices | Hepatic Encephalopathy
Item
evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy
boolean
C4075847 (UMLS CUI [1])
C0003962 (UMLS CUI [2])
C0333106 (UMLS CUI [3])
C0019151 (UMLS CUI [4])
Diabetes | Hypertensive disease | On examination - eye findings Clinical Significance
Item
diabetes and/or hypertension with clinically significant ocular examination findings
boolean
C0011847 (UMLS CUI [1])
C0020538 (UMLS CUI [2])
C0437530 (UMLS CUI [3,1])
C2826293 (UMLS CUI [3,2])
Condition Interferes with Study Subject Participation Status | Condition Interferes with Completion of clinical trial
Item
any condition the could interfere with participation in and completion of the trial
boolean
C0348080 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C2732579 (UMLS CUI [2,3])
Malignant Neoplasms | Malignant Neoplasm Suspected | Exception Carcinoma in Situ Treated | Exception Basal cell carcinoma Treated
Item
evidence of active or suspected malignancy, or history of malignancy within the last 5 years (except adequately treatment carcinoma in situ and basal cell carcinoma of the skin)
boolean
C0006826 (UMLS CUI [1])
C0006826 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007099 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0007117 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
Pregnancy | Breast Feeding
Item
pregnant or breast-feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video